Figure 1.

Cancer‐associated fibroblasts result in the acquisition of chemo‐resistance in lung cancer. A, Quantification of the cancer‐associated fibroblasts (CAF, CD90⁺ cells) in chemo‐sensitive (CS, n = 10) and chemo‐resistant (CR, n = 10) lung cancer patients by flow cytometry. B, α‐SMA expression in CS and CR samples by immunohistochemistry staining. Scale bar is 50 μm. C, MTT assay of A549 cells treated by different concentrations of cisplatin, etoposide and vinorelbine detartrate, respectively, with or without CS or CR CAF pre‐co‐cultured (n = 3). D, The MTT assay of the primary lung cancer patient cells (LCP1) treated with different concentrations of cisplatin, etoposide and vinorelbine detartrate, respectively, with or without CS or CR CAF pre‐co‐cultured (n = 3). The data are presented as the means ± SEM from 3 independent experiments. * P < .05; ** P < .01; *** P < .001; ns, not statistically significant